40
Participants
Start Date
June 5, 2017
Primary Completion Date
March 2, 2021
Study Completion Date
March 2, 2021
Pirfenidone
This is a single-center, randomized, double-blind, placebo-controlled, efficacy and safety study of pirfenidone in subjects with FHP. Approximately 42-45 subjects will be randomized in a 2:1 ratio to receive pirfenidone 2403 mg/d or placebo for 52 weeks.
Placebo controlled
This is a single-center, randomized, double-blind, placebo-controlled, efficacy and safety study of pirfenidone in subjects with FHP. Approximately 42-45 subjects will be randomized in a 2:1 ratio to receive pirfenidone 2403 mg/d or placebo for 52 weeks.
National Jewish Health, Denver
Collaborators (1)
Genentech, Inc.
INDUSTRY
Evans Fernandez Perez
OTHER